Summit Therapeutics, Inc. (SMMT)
16.76
+0.06
(+0.39%)
USD |
NASDAQ |
Oct 02, 16:00
16.75
0.00 (0.00%)
After-Hours: 04:01
Summit Therapeutics Enterprise Value : 12.62B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 12.62B |
| October 01, 2026 | 12.57B |
| September 30, 2026 | 12.74B |
| September 29, 2026 | 12.33B |
| September 28, 2026 | 11.61B |
| September 25, 2026 | 11.71B |
| September 24, 2026 | 12.32B |
| September 23, 2026 | 12.38B |
| September 22, 2026 | 12.91B |
| September 21, 2026 | 12.73B |
| September 18, 2026 | 13.49B |
| September 17, 2026 | 13.38B |
| September 16, 2026 | 13.05B |
| September 15, 2026 | 13.13B |
| September 14, 2026 | 13.94B |
| September 11, 2026 | 13.25B |
| September 10, 2026 | 12.81B |
| September 09, 2026 | 13.24B |
| September 08, 2026 | 13.03B |
| September 04, 2026 | 13.29B |
| September 03, 2026 | 12.92B |
| September 02, 2026 | 10.91B |
| September 01, 2026 | 10.56B |
| August 31, 2026 | 10.13B |
| August 28, 2026 | 10.22B |
| Date | Value |
|---|---|
| August 27, 2026 | 10.69B |
| August 26, 2026 | 10.62B |
| August 25, 2026 | 9.925B |
| August 24, 2026 | 9.426B |
| August 21, 2026 | 9.767B |
| August 20, 2026 | 9.188B |
| August 19, 2026 | 9.727B |
| August 18, 2026 | 9.497B |
| August 17, 2026 | 9.465B |
| August 14, 2026 | 9.918B |
| August 13, 2026 | 10.43B |
| August 12, 2026 | 11.31B |
| August 11, 2026 | 11.32B |
| August 10, 2026 | 11.12B |
| August 07, 2026 | 10.40B |
| August 06, 2026 | 10.07B |
| August 05, 2026 | 10.06B |
| August 04, 2026 | 10.24B |
| August 03, 2026 | 9.676B |
| July 31, 2026 | 9.656B |
| July 30, 2026 | 9.989B |
| July 29, 2026 | 9.481B |
| July 28, 2026 | 9.283B |
| July 27, 2026 | 9.723B |
| July 24, 2026 | 10.16B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| NovelStem International Corp. | 2.190M |
| Brainstorm Cell Therapeutics, Inc. | 11.62M |
| Kezar Life Sciences, Inc. | -11.12M |
| Protara Therapeutics, Inc. | 19.78M |
| Clene, Inc. | 64.81M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -215.70M |
| Total Expenses (Quarterly) | 215.70M |
| EPS Diluted (Quarterly) | -0.2772 |
| Earnings Yield | -6.68% |
| Normalized Earnings Yield | -6.680 |